Match!

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Published on Dec 1, 2017in Cardiovascular Diabetology5.948
· DOI :10.1186/s12933-017-0515-9
Katherine J. Kearney2
Estimated H-index: 2
(University of Leeds),
Darren C. Tomlinson23
Estimated H-index: 23
(University of Leeds)
+ 1 AuthorsRamzi Ajjan33
Estimated H-index: 33
(University of Leeds)
Abstract
An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed of a skeleton of fibrin fibres with cellular elements embedded in this network. Diabetes is characterised by quantitative and qualitative changes in coagulation proteins, which collectively increase resistance to fibrinolysis, consequently augmenting thrombosis risk. Current long-term therapies to prevent arterial occlusion in diabetes are focussed on anti-platelet agents, a strategy that fails to address the contribution of coagulation proteins to the enhanced thrombotic milieu. Moreover, antiplatelet treatment is associated with bleeding complications, particularly with newer agents and more aggressive combination therapies, questioning the safety of this approach. Therefore, to safely control thrombosis risk in diabetes, an alternative approach is required with the fibrin network representing a credible therapeutic target. In the current review, we address diabetes-specific mechanistic pathways responsible for hypofibrinolysis including the role of clot structure, defects in the fibrinolytic system and increased incorporation of anti-fibrinolytic proteins into the clot. Future anti-thrombotic therapeutic options are discussed with special emphasis on the potential advantages of modulating incorporation of the anti-fibrinolytic proteins into fibrin networks. This latter approach carries theoretical advantages, including specificity for diabetes, ability to target a particular protein with a possible favourable risk of bleeding. The development of alternative treatment strategies to better control residual thrombosis risk in diabetes will help to reduce vascular events, which remain the main cause of mortality in this condition.
  • References (194)
  • Citations (12)
📖 Papers frequently viewed together
118 Citations
73 Citations
1 Author (K. Hess)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References194
Newest
#1Setor K. Kunutsor (UoB: University of Bristol)H-Index: 27
#2Samuel Seidu (Leicester General Hospital)H-Index: 10
Last. Kamlesh Khunti (Leicester General Hospital)H-Index: 66
view all 3 authors...
Aims To evaluate the benefits and harms of aspirin for the primary prevention of cardiovascular disease and all-cause mortality events in people with diabetes by conducting a systematic review and meta-analysis. Methods Randomized controlled trials of aspirin compared with placebo (or no treatment) in people with diabetes with no history of cardiovascular disease were identified from MEDLINE, EMBASE, Web of Science, the Cochrane Library and a manual search of bibliographies to November 2015. Stu...
26 CitationsSource
#1Xiaohua ZhouH-Index: 3
Last. Paul DeclerckH-Index: 46
view all 5 authors...
Plasminogen activator inhibitor 1 (PAI-1) is the principal physiological inhibitor of tissue-type plasminogen activator (t-PA) and has been identified as a risk factor in cardiovascular diseases. In order to generate nanobodies against PAI-1 to interfere with its functional properties, we constructed three nanobody libraries upon immunisation of three alpacas with three different PAI-1 variants. Three panels of nanobodies were selected against these PAI-1 variants. Evaluation of the amino acid s...
3 CitationsSource
#1Frederik DenormeH-Index: 9
#2Tine WyseureH-Index: 5
Last. Simon F. De MeyerH-Index: 13
view all 9 authors...
Background and Purpose— Cerebral ischemia and reperfusion is associated with activation of the coagulation cascade and fibrin deposition in cerebral microvessels. Both thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) attenuate fibrinolysis and are therefore attractive targets for the treatment of ischemic stroke. Methods— TAFI and PAI-1 were inhibited by monoclonal antibodies in a mouse model of transient middle cerebral artery occlusion. Twenty-fo...
18 CitationsSource
#1Lina Badimon (Autonomous University of Barcelona)H-Index: 71
#2Rosa SuadesH-Index: 12
Last. Teresa PadróH-Index: 33
view all 5 authors...
Reports in the last decade have suggested that the role of platelets in atherosclerosis and its thrombotic complications may be mediated, in part, by local secretion of platelet-derived microvesicles (pMVs), small cell blebs released during the platelet activation process. MVs are the most abundant cell-derived microvesicle subtype in the circulation. High concentrations of circulating MVs have been reported in patients with atherosclerosis, acute vascular syndromes, and/or diabetes mellitus, su...
34 CitationsSource
National Research Foundation (NRF) of South Africa (91548: Competitive Program) and Medical Research Council (MRC) of South Africa (Self-Initiated Research Program: A0× 331). Grant holder: E Pretorius.
48 CitationsSource
#1Xiaohua Zhou (Katholieke Universiteit Leuven)H-Index: 3
#2Stephen D. Weeks (Katholieke Universiteit Leuven)H-Index: 12
Last. Paul Declerck (Katholieke Universiteit Leuven)H-Index: 46
view all 6 authors...
5 CitationsSource
#1Steven P. Marso (UTSW: University of Texas Southwestern Medical Center)H-Index: 47
#2Gilbert H. Daniels (Harvard University)H-Index: 44
Last. John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 97
view all 15 authors...
BackgroundThe cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. MethodsIn this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The prima...
1,905 CitationsSource
Anatomic pathology studies performed over 150 years ago revealed that excessive activation of coagulation occurs in the setting of inflammation. However, it has taken over a century since these seminal observations were made to delineate the molecular mechanisms by which these systems interact and the extent to which they participate in the pathogenesis of multiple diseases. There is, in fact, extensive cross talk between coagulation and inflammation, whereby activation of one system may amplify...
65 CitationsSource
#1Prashilla Soma (University of Pretoria)H-Index: 12
#2Albe C. Swanepoel (University of Pretoria)H-Index: 10
Last. Etheresia Pretorius (University of Pretoria)H-Index: 33
view all 5 authors...
Background The function of platelets have extended way beyond the horizon of haemostasis and thrombosis, and are recognised as active participants in vascular inflammation, as well as in prothrombotic complications of cardiovascular diseases. We describe and compare platelet function in type II diabetes (with and without cardiovascular manifestation) and healthy individuals using scanning electron microscopy and flow cytometry.
21 CitationsSource
#1D. Leenaerts (University of Antwerp)H-Index: 3
#2J. M. BosmansH-Index: 1
Last. Dirk Hendriks (University of Antwerp)H-Index: 29
view all 6 authors...
Summary Background Two decades after its discovery, carboxypeptidase U (CPU, CPB2 or TAFIa) has become a compelling drug target in thrombosis research. However, given the difficulty of measuring CPU in the blood circulation and the demanding sample collecton requirements, previous clinical studies focused mainly on measuring its inactive precursor, proCPU (proCPB2 or TAFI). Objectives Using a sensitive and specific enzymatic assay, we investigated plasma CPU levels in patients presenting with ac...
4 CitationsSource
Cited By12
Newest
Source
#1Christian Valladolid (BCM: Baylor College of Medicine)H-Index: 1
#2Marina Martinez-Vargas (BCM: Baylor College of Medicine)
Last. Rolando E. Rumbaut (BCM: Baylor College of Medicine)H-Index: 25
view all 12 authors...
Systemic inflammation can lead to coagulopathy and disseminated intravascular coagulation (DIC). In prior studies, the recombinant A2 domain of human von Willebrand factor (VWF; A2 protein) attenuated DIC and decreased mortality in lipopolysaccharide (LPS)-treated mice. Here, we performed studies to dissect the mechanism by which the A2 protein moderates DIC. We used confocal microscopy to analyze the fibrin clot structure in plasma from healthy humans and endotoxemic mice, turbidity assays to e...
Source
#1R. C. Sagar (University of Leeds)
#2K. M. Naseem (University of Leeds)
Last. Ramzi Ajjan (University of Leeds)H-Index: 33
view all 3 authors...
Cardiovascular complications remain the main cause of mortality and morbidity in diabetes. This is related to advanced vascular pathology in this population, together with an enhanced thrombotic environment. The increased risk in thrombosis is secondary to platelet hyper-reactivity and increased levels and/or altered activity of coagulation factors. The current review is focused on the role of antiplatelet agents in modulating the thrombotic milieu in diabetes and improving vascular outcome in t...
Source
#1Ioannis Margaritis (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 1
#2Katerina Angelopoulou (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 10
Last. Dimitrios Kouretas (UTH: University of Thessaly)H-Index: 23
view all 11 authors...
Background: Diabetes is regarded as an epidemiological threat for the twenty-first century. Phytochemicals with known pharmaceutical properties have gained interest in the field of alleviating secondary complications of diseases. Such a substance is crocin, a basic constituent of saffron (Crocus sativus). The present study aimed at examining the beneficial effects of per os crocin administration on the antioxidant status, blood biochemical profile, hepatic gene expression and plasminogen activat...
Source
#1Wael Sumaya (University of Sheffield)H-Index: 4
#2Lars Wallentin (Uppsala University)H-Index: 124
Last. Robert F. Storey (University of Sheffield)H-Index: 63
view all 8 authors...
Hypofibrinolysis is a key abnormality in diabetes but the role of impaired clot lysis in predicting vascular events and mortality in this population is yet to be determined. We aimed to investigate the relationship between fibrin clot properties and clinical outcomes in patients with diabetes and recent acute coronary syndrome (ACS). Plasma samples were collected at hospital discharge from 974 ACS patients with diabetes randomised to clopidogrel or ticagrelor in the PLATO trial. A validated turb...
Source
#1Judith J. de Vries (EUR: Erasmus University Rotterdam)
#2Charlotte J.M. Snoek (EUR: Erasmus University Rotterdam)
Last. Moniek P.M. de Maat (EUR: Erasmus University Rotterdam)H-Index: 40
view all 4 authors...
OBJECTIVE: Post-translational modifications of fibrinogen influence the occurrence and progression of thrombotic diseases. In this systematic review, we assessed the current literature on post-translational modifications of fibrinogen and their effects on fibrin formation and clot characteristics. Approach and Results: A systematic search of Medline, Embase, Cochrane Library, and Web of Science was performed to find studies reporting post-translational modifications of fibrinogen and the effects...
Source
#1Bianca Rocca (CUA: The Catholic University of America)H-Index: 35
#2Carlo Patrono (CUA: The Catholic University of America)H-Index: 81
Abstract Although the improved control of hyperglycaemia and other cardiovascular risk factors was associated with a parallel decline of atherosclerotic cardiovascular disease (ASCVD) and death in both type 1 (T1) and type 2 (T2) diabetes mellitus (DM), the burden of death and hospitalization for ASCVD remains significantly higher by about 2-fold versus the matched non-DM population. Life style interventions, such as physical activity and healthy diet, and drugs, such as statins and low-dose asp...
Source
#1Francesco CosentinoH-Index: 47
#2Peter J. GrantH-Index: 66
Last. Tahseen Ahmad ChowdhuryH-Index: 1
view all 128 authors...
150 CitationsSource
#1William A.E. Parker (University of Sheffield)H-Index: 4
#2Christian Schulte ('KCL': King's College London)H-Index: 6
Last. Ramzi Ajjan (University of Leeds)H-Index: 33
view all 9 authors...
Background Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM.
1 CitationsSource
Abstract Background The post-translational protein modification via lysine residues can significantly alter its function. α2-antiplasmin, a key inhibitor of fibrinolysis, contains 19 lysine residues. Aim We sought to identify sites of glycation and acetylation in human α2-antiplasmin and test whether the competition might occur on the lysine residues of α2-antiplasmin. Methods We analyzed human α2-antiplasmin (1) untreated; (2) incubated with increasing concentrations of β- d -glucose (0, 5, 10,...
Source